quinoline/nausea

Krækjan er vistuð á klemmuspjaldið

Veldu tegund tegund

12 niðurstöður

Neuroanatomical and pharmacological assessment of Fos expression induced in the rat brain by the phosphodiesterase-4 inhibitor 6-(4-pyridylmethyl)-8-(3-nitrophenyl) quinoline.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

A major obstacle in the therapeutic development of phosphodiesterase-4 (PDE4) inhibitors is the production of adverse side effects such as nausea and vomiting. Immunohistochemical detection of Fos-like immunoreactivity (FLI) was used to address the neuroanatomical basis for the pharmacological

Norfloxacin: a quinoline antibiotic.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Norfloxacin is a quinoline (quinolinecarboxylic acid) that should prove successful in treating infections that currently require hospitalization and intravenous antibiotics. Although a nalidixic acid derivative, it possesses greater antibacterial activity against gram-positive and gram-negative

Absence of significant pharmacokinetic and pharmacodynamic interactions between artemether and quinoline antimalarials.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

The study was carried out to investigate the pharmacokinetic and pharmacodynamic interactions between artemether (ARTEM) and quinoline antimalarials namely mefloquine (MQ), quinine (QN) and primaquine (PQ) when given concurrently. A randomised comparative, seven way cross-over design was performed

Effect of CV 205-502 in hyperprolactinaemic patients intolerant of bromocriptine.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

CV 205-502 (Sandoz), an octahydrobenzol [g]quinoline, is a long-acting dopamine agonist which inhibits prolactin secretion. We conducted a phase 2 clinical study in 10 hyperprolactinaemic women (nine of whom were previously intolerant of bromocriptine) in order to determine (1) the dose at which CV

Bosutinib: a novel second-generation tyrosine kinase inhibitor.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Bosutinib (SKI-606) is a 4-anilino-3-quinoline carbonitrile, which acts as a dual inhibitor of Src and ABL kinases. In addition, the BCR-ABL fusion gene product, a constitutively activated tyrosine kinase which is crucial for the development of chronic myeloid leukemia (CML), is highly sensitive to

Clinical features and management of poisoning due to antimalarial drugs.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

The toxicities of antimalarial drugs vary because of the differences in the chemical structures of these compounds. Quinine, the oldest antimalarial, has been used for 300 years. Of the 200 to 300 compounds synthesised since the first synthetic antimalarial, primaquine in 1926, 15 to 20 are

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND Tasquinimod is a quinoline-3-carboxamide derivative with anti-angiogenic activity. Two open-label phase I clinical trials in patients were conducted to evaluate the safety and tolerability of tasquinimod, with additional pharmacokinetic and efficacy assessments. METHODS Patients with

Linomide and interleukin-2 in patients with advanced renal cell carcinoma.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Quinoline-3-carboxamide (Linomide) is a novel, synthetic immunomodulator acting via immunologic and non-immunologic mechanisms. It has shown efficacy against various malignancies, experimental autoimmune encephalomyelitis, and septic shock in animal models and has been investigated for clinical use

Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Brequinar (DUP 785, NSC 368390) is a 4-quinoline carboxylic acid derivative with broad spectrum antitumour activity in experimental models that acts as an antimetabolite by specific inhibition of de novo pyrimidine synthesis. We performed a phase I study of brequinar administered as a 10 min

Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Brequinar sodium (DUP 785, NSC 368390) is a novel quinoline-carboxylic acid derivative that has been selected for clinical evaluation because of its broad spectrum of antitumor activity in animal models and its novel chemical structure. This compound inhibits the mitochondrial enzyme dihydroorotate

Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Brequinar sodium is a quinoline carboxylic acid derivative that has shown antitumor activity in a number of in vivo murine and human tumor xenograft models. Its mechanism of action is blockade of de novo pyrimidine biosynthesis by inhibition of dihydroorotic acid dehydrogenase. In vitro and in vivo

Understanding malarial toxins.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Recognized since antiquity, malaria is one of the most infamous and widespread infectious diseases in humans and, although the death rate during the last century has been diminishing, it still accounts for more than a half million deaths annually. It is caused by the Plasmodium parasite and typical

Skráðu þig á
facebook síðu okkar

Herbal & Natural Medicine

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

Virkar á 55 tungumálum
Jurtalækningar studdir af vísindum
Jurtaviðurkenning eftir ímynd
Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
Lestu vísindarit sem tengjast leit þinni
Leitaðu að lækningajurtum eftir áhrifum þeirra
Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum